Hannah Joseph Hospital IPO GMP is currently at ₹0 as of 20 January 2026, based on the latest activity in the grey market. The grey market premium gives an early indication of how the IPO is being perceived by informal market participants before its official listing.
The IPO has an upper price band of 70 per share. Based on the current Hannah Joseph Hospital IPO GMP, the estimated listing price is around ₹70 (0.00%) per share. At the current level, the GMP indicate weak sentiment ahead of listing. A positive GMP usually reflects decent investor interest, while a lower GMP signals cautious sentiment.
Highest GMP value of Hannah Joseph Hospital IPO: 0 on 20 January 2026
Lowest GMP value of Hannah Joseph Hospital IPO: 0 on 19 January 2026
Contents
Hannah Joseph Hospital IPO Day-wise GMP Trend
| Date | IPO Price | GMP | Est. Listing | Gain | Trend |
|---|---|---|---|---|---|
| 20-Jan-2026 | ₹70 | ₹0 | ₹70 | 0% | FLAT |
| 19-Jan-2026 | ₹70 | ₹0 | ₹70 | 0% | FLAT |
Disclaimer: IPO GMP, Kostak, and Subject to Sauda (Sub2) rates are unofficial and shared for informational purposes only. We do not trade or recommend participation in the grey market. GMP is not a guarantee of listing performance. Investors should apply after reviewing the company’s fundamentals and official offer documents.
Hannah Joseph Hospital IPO Details
| Particular | Details |
|---|---|
| IPO Open Date | January 22, 2026 |
| IPO Close Date | January 27, 2026 |
| Face Value | ₹10 per equity share |
| IPO Price Band | ₹67 to ₹70 per share |
| Issue Size | Approx ₹42 Crores |
| Fresh Issue | Approx ₹42 Crores |
| Offer for Sale | Approx [.] Equity Shares |
| Issue Type | Book Built Issue |
| IPO Listing | BSE SME |
| DRHP Draft Prospectus | View PDF |
| RHP Draft Prospectus | View PDF |
Also Read: Hannah Joseph Hospital IPO
Hannah Joseph Hospital IPO Dates
| Event | Date |
|---|---|
| IPO Open Date | January 22, 2026 |
| IPO Close Date | January 27, 2026 |
| Basis of Allotment | January 28, 2026 |
| Refunds | January 29, 2026 |
| Credit to Demat Account | January 29, 2026 |
| IPO Listing Date | January 30, 2026 |
| IPO Bidding Cut-off Time | January 27, 2026 – 5 PM |
Hannah Joseph Hospital Lots Details
| Activity | Date |
|---|---|
| Issue Price | ₹67.00-70.00 |
| Market Lot | 1,500 Shares |
| Individual Investor | ₹2,10,000 |
| Min HNI Lots | 4500 shares (3 lots) |
Hannah Joseph Hospital Business & Financial Health
Hannah Joseph Hospital operates in the regional healthcare space with a focus on specialised medical services. The company has demonstrated consistent revenue growth from FY2023 to FY2025, supported by higher patient inflow and improved service offerings. Profitability has strengthened in FY2025, and margins have expanded due to better cost control and operational efficiency.
The balance sheet remains stable, with a manageable debt-to-equity ratio of 0.65. The proposed investment in a Radiation Oncology Centre is expected to enhance long-term revenue visibility and diversify service lines. Overall, the company shows improving financial health with scope for sustainable growth.
Hannah Joseph Hospital GMP FAQs
What is the latest Hannah Joseph Hospital IPO GMP today?
The current GMP is ₹0 as of 20 January 2026. It reflects the unofficial grey market sentiment ahead of the listing.
What is the estimated listing price of Hannah Joseph Hospital IPO?
Estimated listing price is around ₹70 (0.00%) per share of Hannah Joseph Hospital IPO. Actual listing price may differ.
What is the minimum market lot for Hannah Joseph Hospital SME IPO?
The minimum market lot size is 1,500 shares, requiring an investment of approximately ₹2,10,000 at the issue price.
What is the estimated profit per lot in Hannah Joseph Hospital IPO?
The estimated profit is calculated as:
Market lot size × GMP = Estimated Profit
Expert Review
Hannah Joseph Hospital IPO GMP at ₹0 reflects subdued grey market sentiment and limited short-term listing expectations. The flat GMP trend indicates that investors are taking a cautious approach.
While the hospital shows improving financial performance and stable leverage, listing gains may remain muted. Long-term investors should evaluate healthcare expansion plans, margins, and execution capability beyond GMP signals.
